CSPC Pharmaceutical reported a 10.3% year-on-year revenue increase and a 31.4% rise in adjusted net profit for 2025, driven by strong sales of innovative products. Despite lowering the target price due to expected revenue downgrades, the firm maintains a 'Buy' rating, anticipating steady growth in revenue and profit over the next few years.
